Health state utilities for metastatic breast cancer in Taiwan

BACKGROUND: New developments in medications for metastatic breast cancer (MBC) can be of great benefit to patients, but unfortunately these medicines also increase expenditures. Cost-utility analyses (CUAs) are needed to allocate health resources properly, and health utility values are required to c...

Descripción completa

Detalles Bibliográficos
Autores principales: Chou, Tzu-Chun, Chiang, Shao-Chin, Ko, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377330/
https://www.ncbi.nlm.nih.gov/pubmed/32213442
http://dx.doi.org/10.1016/j.breast.2020.03.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377330/
https://www.ncbi.nlm.nih.gov/pubmed/32213442
http://dx.doi.org/10.1016/j.breast.2020.03.001

Ejemplares similares